Dr. Nallapareddy is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
22 W Dry Creek Cir
Littleton, CO 80120Phone+1 303-730-4700Fax+1 303-730-4790
Education & Training
University of ColoradoFellowship, Hematology and Medical Oncology, 2006 - 2009
University at BuffaloResidency, Internal Medicine, 2003 - 2006
Osmania Medical College NTR UHSClass of 2000
Certifications & Licensure
CO State Medical License 2007 - 2025
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Publications & Presentations
PubMed
- 411 citationsSafety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trialJeffrey R. Infante, Leslie A. Fecher, Gerald S. Falchook, Sujatha Nallapareddy, Michael S. Gordon
The Lancet. Oncology. 2012-08-01 - 38 citationsPreclinical Activity of the Rational Combination of Selumetinib (AZD6244) in Combination with Vorinostat in KRAS Mutant Colorectal Cancer ModelsM. Pia Morelli, John J. Tentler, Gillian N. Kulikowski, Aik Choon Tan, Erica L. Bradshaw-Pierce
Clinical Cancer Research. 2012-02-15 - 64 citationsIdentification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer.John J. Tentler, Sujatha Nallapareddy, Aik Choon Tan, Anna Spreafico, Todd M. Pitts
Molecular Cancer Therapeutics. 2010-12-01
Press Mentions
OncLive® Hosts the Latest State of the Science Summit™ on Gastrointestinal MalignanciesMay 3rd, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
